Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial

Podobne knjige/članki

• Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial
  od: Sh. Erdes, et al.
  Izdano: (2019-12-01)
• Structural basis for the inhibition of RecBCD by Gam and its synergistic antibacterial effect with quinolones
  od: Martin Wilkinson, et al.
  Izdano: (2016-12-01)
• Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
  od: D. E. Karateev, et al.
  Izdano: (2017-09-01)
• COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
  od: A. M. Lila, et al.
  Izdano: (2018-07-01)
• Design of High Speed BCD Adder Using CMOS Technology
  od: Abdelsalam Al Share, et al.
  Izdano: (2023-01-01)